scholarly journals Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation

Blood ◽  
1991 ◽  
Vol 77 (3) ◽  
pp. 649-653 ◽  
Author(s):  
RJ Jones ◽  
RF Ambinder ◽  
S Piantadosi ◽  
GW Santos
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Salvage Therapy ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Event Free Survival ◽  
Free Survival ◽  
Allogeneic Bmt

Abstract The existence of an immunologic antileukemia reaction associated with allogeneic bone marrow transplantation (BMT) is well established. However, a similar graft-versus-tumor effect against lymphomas has not been demonstrated. We analyzed the results of BMT in 118 consecutive patients with relapsed Hodgkin's disease or aggressive non-Hodgkin's lymphoma. The 38 patients less than 50 years of age with HLA-matched donors had allogenic marrow transplants, and the other 80 patients received purged autologous grafts. The median age was 26 years in both the allogeneic and the autologous graft recipients. The patient's response to conventional salvage therapy before transplant was the only factor that influenced the event-free survival after BMT (P less than .001). Both the patient's response to salvage therapy before BMT (P less than .001) and the type of graft (P = .02) significantly influenced the probability of relapse after BMT. The actuarial probability of relapse in patients who responded to conventional salvage therapy before BMT was only 18% after allogenic BMT compared with 46% after autologous BMT. However, the actuarial probability of event-free survival at 4 years was the same, 47% versus 41%, for patients with responsive lymphomas who received allogeneic and autologous transplants, respectively (P = .8). The beneficial antitumor effect of allogeneic BMT was offset by its higher transplant-related mortality (P = .01), largely resulting from graft-versus-host disease. Allogeneic BMT appears to induce a clinically significant graft-versus- lymphoma effect. The magnitude of this effect is similar to that reported against leukemias.

scholarly journals Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation

Blood ◽  
1991 ◽  
Vol 77 (3) ◽  
pp. 649-653 ◽  
Author(s):  
RJ Jones ◽  
RF Ambinder ◽  
S Piantadosi ◽  
GW Santos
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Salvage Therapy ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Event Free Survival ◽  
Free Survival ◽  
Allogeneic Bmt

The existence of an immunologic antileukemia reaction associated with allogeneic bone marrow transplantation (BMT) is well established. However, a similar graft-versus-tumor effect against lymphomas has not been demonstrated. We analyzed the results of BMT in 118 consecutive patients with relapsed Hodgkin's disease or aggressive non-Hodgkin's lymphoma. The 38 patients less than 50 years of age with HLA-matched donors had allogenic marrow transplants, and the other 80 patients received purged autologous grafts. The median age was 26 years in both the allogeneic and the autologous graft recipients. The patient's response to conventional salvage therapy before transplant was the only factor that influenced the event-free survival after BMT (P less than .001). Both the patient's response to salvage therapy before BMT (P less than .001) and the type of graft (P = .02) significantly influenced the probability of relapse after BMT. The actuarial probability of relapse in patients who responded to conventional salvage therapy before BMT was only 18% after allogenic BMT compared with 46% after autologous BMT. However, the actuarial probability of event-free survival at 4 years was the same, 47% versus 41%, for patients with responsive lymphomas who received allogeneic and autologous transplants, respectively (P = .8). The beneficial antitumor effect of allogeneic BMT was offset by its higher transplant-related mortality (P = .01), largely resulting from graft-versus-host disease. Allogeneic BMT appears to induce a clinically significant graft-versus- lymphoma effect. The magnitude of this effect is similar to that reported against leukemias.

scholarly journals Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation

2012 ◽  
Vol 209 (5) ◽  
pp. 903-911 ◽  
Author(s):  
Robert R. Jenq ◽  
Carles Ubeda ◽  
Ying Taur ◽  
Clarissa C. Menezes ◽  
Raya Khanin ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Intestinal Inflammation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Allogeneic Bmt ◽  
Initial Onset ◽  
Human Flora

Despite a growing understanding of the link between intestinal inflammation and resident gut microbes, longitudinal studies of human flora before initial onset of intestinal inflammation have not been reported. Here, we demonstrate in murine and human recipients of allogeneic bone marrow transplantation (BMT) that intestinal inflammation secondary to graft-versus-host disease (GVHD) is associated with major shifts in the composition of the intestinal microbiota. The microbiota, in turn, can modulate the severity of intestinal inflammation. In mouse models of GVHD, we observed loss of overall diversity and expansion of Lactobacillales and loss of Clostridiales. Eliminating Lactobacillales from the flora of mice before BMT aggravated GVHD, whereas reintroducing the predominant species of Lactobacillus mediated significant protection against GVHD. We then characterized gut flora of patients during onset of intestinal inflammation caused by GVHD and found patterns mirroring those in mice. We also identified increased microbial chaos early after allogeneic BMT as a potential risk factor for subsequent GVHD. Together, these data demonstrate regulation of flora by intestinal inflammation and suggest that flora manipulation may reduce intestinal inflammation and improve outcomes for allogeneic BMT recipients.

scholarly journals Interleukin-1 administration before lethal irradiation and allogeneic bone marrow transplantation: early transient increase of peripheral granulocytes and successful engraftment with accelerated leukocyte, erythrocyte, and platelet recovery

Blood ◽  
1993 ◽  
Vol 81 (7) ◽  
pp. 1933-1939 ◽  
Author(s):  
P Tiberghien ◽  
V Laithier ◽  
M Mabed ◽  
E Racadot ◽  
CW Reynolds ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Marrow Cell ◽  
Interleukin 1 ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Allogeneic Bmt ◽  
Lethal Irradiation

Administration of interleukin-1 beta (IL-1 beta) before a lethal irradiation with or without allogeneic bone marrow transplantation (BMT) protects greater than 90% of the irradiated mice. To approach the mechanisms responsible for the radioprotective effect of IL-1, we examined the effects of IL-1 pretreatment on engraftment and kinetics of peripheral blood, spleen, and marrow cell reconstitution after irradiation and BMT. Although the BMT was not necessary for the survival of the IL-1-pretreated lethally irradiated mice, allogeneic marrow did engraft in these mice as evaluated in the spleen and marrow 2 months after BMT. IL-1 pretreatment significantly accelerated hematopoietic recovery versus transplanted saline-treated controls with a pronounced enhancement of peripheral leukocyte, platelet, and erythrocyte recovery. Leukocyte recovery in IL-1-pretreated mice was unique in that IL-1 first induced an early transient (maximum at day 7) increase of peripheral granulocytes before accelerating leukocyte recovery after day 11. IL-1 pretreatment also significantly enhanced marrow cell recovery after allogeneic BMT with an eightfold increase in marrow cellularity from day 4 to 11 versus control transplanted mice. When lethal irradiation was not followed by allogeneic BMT. IL-1 pretreatment also affected the peripheral reconstitution of leukocytes, platelets, and erythrocytes. Interestingly, in the absence of BMT, IL-1 also induced an early circulation of peripheral granulocytes. Overall, our data demonstrate that a single administration of IL-1 before lethal irradiation and allogeneic BMT can induce an early transient increase of circulating granulocytes, followed by an accelerated multilineage recovery and long-term allogeneic engraftment.

The Change of Vascular Endothelial Growth Factor and Microvessel Density Following Imatinib Mesylate Therapy and Allogeneic Bone Marrow Transplantation in Chronic Myeolid Leukemia.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4669-4669
Author(s):  
Jae-Yong Kwak ◽  
Na-Ri Lee ◽  
Eun-Gi Song ◽  
Chang-Yeol Yim ◽  
Myoung-Ja Chung ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Imatinib Mesylate ◽  
Bone Marrow Biopsy ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Allogeneic Bmt ◽  
Significant Difference

Abstract Chronic myeloid leukemia(CML) is a clonal myeloproliferative disorder and increased angiogenesis in bone marrow is a feature of CML. Vascular endothelial growth factor(VEGF) is a potent angiogenic peptide and microvessel density(MVD) is increased in bone marrow of CML. In this study, the effect of imatinib mesylate therapy on angiogeneisis was investigated and compared with allogeneic bone marrow transplantation(BMT) with philadelphia chromosome positive/BCR-ABL+ CML in first chronic phase. Immunohistochemical staining for detecting VEGF protein was performed by labeled avidin-biotin method on the formalin-fixed and paraffin embedded bone marrow biopsy samples of 10patients of allogeneic BMT, 20patients of imatinib mesylate therapy and 10normal control. Initial and sequential, after at least 12 months of therapy, bone marrow biopsy examed and all patients achieved complete cytogenetic remission. Microvessel was scored in at least 3 areas(*200 fields) of the highest MVD in representative sections of each bone marrow biopsy specimen using immunohistochemistry for CD32 antigen. Patients with Imatinib mesylate therapy and allogeneic BMT induced a significant reduction of MVD (normalization in comparison with controls). MVD was no significant difference between the patients with imatinib therapy and allogeneic BMT. VEGF was mainly expressed myeloid progenitors and less abundantly megakaryocytes and mature granulomonocytic cells. Expression of VEGF, it was significantly decreased in patients with Imatinib mesylate therapy and allogeneic BMT(normalization in comparison with controls). VEGF expression was no significant difference between the patients with imatinib therapy and allogeneic BMT. First line therapy with imatinib mesylate was normalization of bone marrow vascularity compared with allogeneic bone marrow transplantation of CML in first chronic phase.

Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.

1995 ◽  
Vol 13 (5) ◽  
pp. 1096-1102 ◽  
Author(s):  
K W van Besien ◽  
I F Khouri ◽  
S A Giralt ◽  
P McCarthy ◽  
R Mehra ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Low Grade ◽  
Allogeneic Bone ◽  
Actuarial Survival ◽  
Prognostic Features ◽  
Allogeneic Bmt

PURPOSE To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. PATIENTS AND METHODS Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. RESULTS Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% +/- 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. CONCLUSION These results compare favorably with those for autologous BMT. Allogeneic BMT offers considerable promise for the treatment of patients with poor-prognosis low-grade lymphoma. Its role should be further defined in prospective studies.

Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors.

1991 ◽  
Vol 9 (10) ◽  
pp. 1848-1859 ◽  
Author(s):  
J H Lundberg ◽  
R M Hansen ◽  
C R Chitambar ◽  
C A Lawton ◽  
M Gottlieb ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Cell ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Low Grade ◽  
Allogeneic Bone ◽  
Free Survival ◽  
Refractory Lymphoma

Twenty-two patients, ages 16.6 to 43.9 years (median age, 30 years), with relapsed or refractory lymphoma were treated by allogeneic bone marrow transplantation after high-dose chemotherapy with or without total body irradiation (TBI). Seven patients had Hodgkin's disease, four had low-grade histology non-Hodgkin's lymphoma (NHL), seven had intermediate-grade NHL, and four had high-grade NHL. Of the 22 patients, 17 received T-cell (CD-3)-depleted marrow after intensive pretransplant chemoradiotherapy, and five received T-cell-replete grafts after chemotherapy-based preparative regimens. Five patients were transplanted from donors other than genotypically HLA-identical siblings: four from partially HLA-matched relatives, and one from a phenotypically HLA-identical unrelated donor. Acute graft-versus-host disease (GVHD) was less than or equal to grade II in all patients, and chronic GVHD was limited or absent in all but one patient. Of the 21 assessable patients, 17 (80.9%) achieved complete remissions. Death due to transplant-associated complications occurred in five patients, and five patients have relapsed. Thirteen patients are alive, and 12 are continuously relapse-free at a median follow-up of longer than 28 months (range, greater than 10 to greater than 58 months) from transplant. The cumulative probability of treatment failure from relapse or progression of lymphoma was 29% (95% confidence interval [CI], 12% to 51%), while the actuarial lymphoma-free (ie, event-free) survival plateau is 54.6% (95% CI, 34% to 76%). For young patients with advanced malignant lymphoma, allogeneic bone marrow transplantation appears superior to salvage chemotherapy for achievement of long-term, lymphoma-free survival and may be preferable to autologous bone marrow transplantation for selected patients.

scholarly journals Interleukin-1 administration before lethal irradiation and allogeneic bone marrow transplantation: early transient increase of peripheral granulocytes and successful engraftment with accelerated leukocyte, erythrocyte, and platelet recovery

Blood ◽  
1993 ◽  
Vol 81 (7) ◽  
pp. 1933-1939 ◽  
Author(s):  
P Tiberghien ◽  
V Laithier ◽  
M Mabed ◽  
E Racadot ◽  
CW Reynolds ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Marrow Cell ◽  
Interleukin 1 ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Allogeneic Bmt ◽  
Lethal Irradiation

Abstract Administration of interleukin-1 beta (IL-1 beta) before a lethal irradiation with or without allogeneic bone marrow transplantation (BMT) protects greater than 90% of the irradiated mice. To approach the mechanisms responsible for the radioprotective effect of IL-1, we examined the effects of IL-1 pretreatment on engraftment and kinetics of peripheral blood, spleen, and marrow cell reconstitution after irradiation and BMT. Although the BMT was not necessary for the survival of the IL-1-pretreated lethally irradiated mice, allogeneic marrow did engraft in these mice as evaluated in the spleen and marrow 2 months after BMT. IL-1 pretreatment significantly accelerated hematopoietic recovery versus transplanted saline-treated controls with a pronounced enhancement of peripheral leukocyte, platelet, and erythrocyte recovery. Leukocyte recovery in IL-1-pretreated mice was unique in that IL-1 first induced an early transient (maximum at day 7) increase of peripheral granulocytes before accelerating leukocyte recovery after day 11. IL-1 pretreatment also significantly enhanced marrow cell recovery after allogeneic BMT with an eightfold increase in marrow cellularity from day 4 to 11 versus control transplanted mice. When lethal irradiation was not followed by allogeneic BMT. IL-1 pretreatment also affected the peripheral reconstitution of leukocytes, platelets, and erythrocytes. Interestingly, in the absence of BMT, IL-1 also induced an early circulation of peripheral granulocytes. Overall, our data demonstrate that a single administration of IL-1 before lethal irradiation and allogeneic BMT can induce an early transient increase of circulating granulocytes, followed by an accelerated multilineage recovery and long-term allogeneic engraftment.

Sign in / Sign up

Export Citation Format

Share Document